Abstract
The Pax-5 gene encodes a B-cell-specific activator protein (BSAP) that plays a key role in B lymphocyte differentiation and embryogenesis. The deregulation of this transcription factor is also linked to B cell malignancies and recently to other cancers. More specifically, the downstream effects of Pax-5 promote cell-cell interactions and mediate the activation of adhesion genes which result in an epithelial phenotypic behavior of human carcinoma cells. To gain a better understanding of Pax-5-mediated gene regulation, we studied available gene expression data in depth and identified several Pax-5 downstream targets. Among these, we found that Pax-5 activity is consistently inversely correlated with the expression of Focal Adhesion Kinase 1 (FAK1). FAK1 is known to enhance migration of cancer cells and promote metastatic dissemination to distant sites. Further analysis looking at genome wide profiling of Pax-5 DNAbinding points to both direct and indirect regulation of FAK1 expression by Pax-5 and its downstream targets. These findings suggest a key role for Pax-5 in phenotypic transitioning during metastasis through the regulation of FAK1 activity.
Keywords: Cancer, cell signaling, FAK1, focal adhesion, metastasis, Pax-5, B lymphopoiesis, cell differentiation, homeostasis, leukemia
Anti-Cancer Agents in Medicinal Chemistry
Title: Coordinated Expression of Pax-5 and FAK1 in Metastasis
Volume: 11 Issue: 7
Author(s): Nicolas Crapoulet, Pierre O'Brien, Rodney J. Ouellette and Gilles A. Robichaud
Affiliation:
Keywords: Cancer, cell signaling, FAK1, focal adhesion, metastasis, Pax-5, B lymphopoiesis, cell differentiation, homeostasis, leukemia
Abstract: The Pax-5 gene encodes a B-cell-specific activator protein (BSAP) that plays a key role in B lymphocyte differentiation and embryogenesis. The deregulation of this transcription factor is also linked to B cell malignancies and recently to other cancers. More specifically, the downstream effects of Pax-5 promote cell-cell interactions and mediate the activation of adhesion genes which result in an epithelial phenotypic behavior of human carcinoma cells. To gain a better understanding of Pax-5-mediated gene regulation, we studied available gene expression data in depth and identified several Pax-5 downstream targets. Among these, we found that Pax-5 activity is consistently inversely correlated with the expression of Focal Adhesion Kinase 1 (FAK1). FAK1 is known to enhance migration of cancer cells and promote metastatic dissemination to distant sites. Further analysis looking at genome wide profiling of Pax-5 DNAbinding points to both direct and indirect regulation of FAK1 expression by Pax-5 and its downstream targets. These findings suggest a key role for Pax-5 in phenotypic transitioning during metastasis through the regulation of FAK1 activity.
Export Options
About this article
Cite this article as:
Crapoulet Nicolas, O'Brien Pierre, J. Ouellette Rodney and A. Robichaud Gilles, Coordinated Expression of Pax-5 and FAK1 in Metastasis, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817637
DOI https://dx.doi.org/10.2174/187152011796817637 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Current Medicinal Chemistry Germ Cell Apoptosis: Relevance to Infertility and Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Caffeic Acid Phenethyl Ester Effects: In Silico Study of its Osteoimmunological Mechanisms
Letters in Drug Design & Discovery Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
Current Topics in Medicinal Chemistry Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Current Gene Therapy Expression of Histone Acetyltransferase GCN5 and Histone Deacetylase 1 in the Cultured Mouse Preimplantation Embryos
Current Pharmaceutical Design Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry